CA3095426A1 - Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives - Google Patents
Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives Download PDFInfo
- Publication number
- CA3095426A1 CA3095426A1 CA3095426A CA3095426A CA3095426A1 CA 3095426 A1 CA3095426 A1 CA 3095426A1 CA 3095426 A CA3095426 A CA 3095426A CA 3095426 A CA3095426 A CA 3095426A CA 3095426 A1 CA3095426 A1 CA 3095426A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- occurrence
- compound
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656041P | 2018-04-11 | 2018-04-11 | |
| US62/656,041 | 2018-04-11 | ||
| PCT/EP2019/059289 WO2019197546A1 (en) | 2018-04-11 | 2019-04-11 | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095426A1 true CA3095426A1 (en) | 2019-10-17 |
Family
ID=66334384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095426A Pending CA3095426A1 (en) | 2018-04-11 | 2019-04-11 | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11858937B2 (https=) |
| EP (1) | EP3774809A1 (https=) |
| JP (2) | JP7406501B2 (https=) |
| KR (1) | KR20200143429A (https=) |
| CN (1) | CN112334471A (https=) |
| AU (1) | AU2019250504B2 (https=) |
| BR (1) | BR112020020645A2 (https=) |
| CA (1) | CA3095426A1 (https=) |
| IL (2) | IL299105B2 (https=) |
| MX (1) | MX2020010563A (https=) |
| MY (1) | MY207194A (https=) |
| PH (1) | PH12020551638A1 (https=) |
| SG (1) | SG11202009466UA (https=) |
| WO (1) | WO2019197546A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| GB201918541D0 (en) | 2019-12-16 | 2020-01-29 | Carrick Therapeutics Ltd | Therapeutic compounds and their use |
| US20250263413A1 (en) * | 2020-12-02 | 2025-08-21 | Qurient Co., Ltd. | Compounds having cyclin-dependent kinase(cdk)-inhibitory function |
| US20240343732A1 (en) * | 2021-05-28 | 2024-10-17 | Qurient Co., Ltd. | Compounds for degradation of cyclin-dependent kinase 7(cdk7) |
| US20250042903A1 (en) * | 2021-06-17 | 2025-02-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Triazine inhibitors of cyclin-dependent kinases |
| EP4493193A1 (en) * | 2022-03-18 | 2025-01-22 | Qurient Co., Ltd. | Cdk7 inhibitors for antiviral treatment |
| US20260041693A1 (en) | 2022-08-05 | 2026-02-12 | Qurient Co., Ltd. | Combination therapy of cdk7 inhibitors with other anti-cancer therapies |
| KR20240095030A (ko) | 2022-12-15 | 2024-06-25 | 부산대학교 산학협력단 | 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법 |
| CN120752238A (zh) * | 2023-02-20 | 2025-10-03 | 江苏正大丰海制药有限公司 | 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用 |
| CN120712267A (zh) * | 2023-02-21 | 2025-09-26 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2025040170A1 (zh) * | 2023-08-24 | 2025-02-27 | 杭州德睿智药科技有限公司 | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 |
| WO2025162425A1 (zh) * | 2024-02-01 | 2025-08-07 | 广州费米子科技有限责任公司 | 吡唑并嘧啶化合物作为tyk2抑制剂 |
| CN119606955A (zh) * | 2024-11-13 | 2025-03-14 | 南方医科大学 | Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US615968A (en) | 1898-12-13 | Apparatus for treating ores | ||
| US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) * | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| EP2634189A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors |
| EP2634190A1 (en) * | 2012-03-01 | 2013-09-04 | Lead Discovery Center GmbH | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors |
| EP3129371B1 (en) | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| ES2899196T3 (es) * | 2015-03-09 | 2022-03-10 | Aurigene Discovery Tech Ltd | Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK |
| WO2019035866A1 (en) * | 2017-08-15 | 2019-02-21 | The Brigham & Women's Hospital, Inc. | COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX |
-
2019
- 2019-04-11 BR BR112020020645-8A patent/BR112020020645A2/pt unknown
- 2019-04-11 MX MX2020010563A patent/MX2020010563A/es unknown
- 2019-04-11 SG SG11202009466UA patent/SG11202009466UA/en unknown
- 2019-04-11 JP JP2020555188A patent/JP7406501B2/ja active Active
- 2019-04-11 CN CN201980039675.8A patent/CN112334471A/zh active Pending
- 2019-04-11 IL IL299105A patent/IL299105B2/en unknown
- 2019-04-11 KR KR1020207032377A patent/KR20200143429A/ko active Pending
- 2019-04-11 CA CA3095426A patent/CA3095426A1/en active Pending
- 2019-04-11 EP EP19720424.1A patent/EP3774809A1/en active Pending
- 2019-04-11 US US17/045,009 patent/US11858937B2/en active Active
- 2019-04-11 MY MYPI2020005131A patent/MY207194A/en unknown
- 2019-04-11 WO PCT/EP2019/059289 patent/WO2019197546A1/en not_active Ceased
- 2019-04-11 AU AU2019250504A patent/AU2019250504B2/en active Active
-
2020
- 2020-09-30 IL IL277694A patent/IL277694A/en unknown
- 2020-10-05 PH PH12020551638A patent/PH12020551638A1/en unknown
-
2023
- 2023-08-14 JP JP2023131905A patent/JP2023138859A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL299105B2 (en) | 2024-02-01 |
| MY207194A (en) | 2025-02-05 |
| JP7406501B2 (ja) | 2023-12-27 |
| US11858937B2 (en) | 2024-01-02 |
| AU2019250504B2 (en) | 2023-05-18 |
| NZ768400A (en) | 2024-07-05 |
| CN112334471A (zh) | 2021-02-05 |
| SG11202009466UA (en) | 2020-10-29 |
| BR112020020645A2 (pt) | 2021-01-12 |
| US20210139483A1 (en) | 2021-05-13 |
| EP3774809A1 (en) | 2021-02-17 |
| MX2020010563A (es) | 2020-10-22 |
| WO2019197546A1 (en) | 2019-10-17 |
| IL299105A (en) | 2023-02-01 |
| AU2019250504A1 (en) | 2020-10-15 |
| JP2023138859A (ja) | 2023-10-02 |
| PH12020551638A1 (en) | 2021-07-26 |
| KR20200143429A (ko) | 2020-12-23 |
| IL299105B1 (en) | 2023-10-01 |
| IL277694A (en) | 2020-11-30 |
| JP2021521129A (ja) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3095426A1 (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
| AU2019250507B2 (en) | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase | |
| AU2019249231B2 (en) | Modulators of proteolysis and associated methods of use | |
| AU2019230209B2 (en) | Amino acid compounds and methods of use | |
| EP3377482B1 (en) | Modulators of ror-gamma | |
| CA2976741C (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| CA3166554A1 (en) | Benzamide containing compounds for modulating brg1- or brm-associated factors_________________________________________________ | |
| CA3008747C (en) | Novel compounds | |
| WO2017158381A1 (en) | 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for trating cancer | |
| EA009337B1 (ru) | Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии | |
| US12606561B2 (en) | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | |
| US20240343732A1 (en) | Compounds for degradation of cyclin-dependent kinase 7(cdk7) | |
| RU2818563C2 (ru) | Фармацевтически активные производные пиразолотриазина и/или пиразолопиримидина | |
| TW202330519A (zh) | 作為ｔａｍ抑制劑的吡唑并吡啶化合物 | |
| RU2809779C2 (ru) | Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы | |
| CN115403581B (zh) | 作为irak4抑制剂的杂环化合物 | |
| HK40055299A (en) | Modulators of ror-gamma | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| HK1261518B (en) | Modulators of ror-gamma | |
| HK1261518A1 (en) | Modulators of ror-gamma | |
| HK1256059B (en) | An inhibitor of deubiquitylating enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240126 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250318 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250318 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250318 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250611 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250728 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250728 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260317 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260317 |